Compared with other racial/ethnic groups, Black patients with type 1 diabetes (T1D) presented to medical centers with diabetic ketoacidosis (DKA) more often throughout the COVID-19 pandemic, regardless of COVID-19 infection.
Data on diabetic ketoacidosis (DKA) rates collected throughout the COVID-19 pandemic revealed Black Americans with type 1 diabetes (T1D) were more likely to develop the life-threatening condition compared with non-Hispanic Whites (NHW) patients.
Findings were published in The Journal of Clinical Endocrinology & Metabolism, and underscored “the urgent need for improved strategies to prevent DKA among patients with T1D—not only under pandemic conditions, but under all conditions—especially among populations most affected by health inequities,” the authors wrote.
Previous research has shown presentations of newly diagnosed T1D have been more severe throughout the pandemic compared with previous years, while patients from minority races/ethnicities with both T1D and COVID-19 were more likely to present to the hospital with DKA.
To better elucidate trends in DKA throughout this time period, independent of COVID-19 infection, researchers with the T1D Exchange Quality Improvement Collaborative (T1DX-QI) carried out a retrospective cohort study using information from 7 US medical centers.
Data were collected between January 2020 and December 2020 and compared with the same time window of 2019.
“Both patients with established T1D who developed DKA and patients with newly diagnosed T1D who presented in DKA at T1D diagnosis were included,” the researchers explained.
A total of 15,267 patients with T1D who presented in 2019 and 15,176 patients who presented in 2020 were included in the analysis. Researchers also specifically assessed data collected during COVID-19 waves taking place between March-May 2020 (surge 1) and August-October 2020 (surge 2).
In addition, no differences in the proportion of patients with DKA based on gender, insurance type, or severity of DKA were found, although in 2020, the proportion of patients with a DKA event was higher in those aged 60 years or over and with a glycated hemoglobin lower than 7%.
Findings illustrate the disruptive nature of the pandemic for patients with T1D, while the DKA rates reported correspond with those seen in other international studies.
Despite the “heightened awareness of racial health inequities during COVID-19 and efforts made to address them, we observed that DKA frequency did not improve among NHB as the pandemic progressed,” authors wrote.
In the current study, Hispanic patients tended to fare better with regard to DKA incidence than NHB patients, a finding consistent with previous research; this could be due to differing inequity contributors in each population.
Differential access to diabetes technologies also may have impacted results as “rates of diabetes technology use are lowest by far among NHB, in part due to social inequities and systemic racism.” However, the current dataset precluded researchers from determining any demographic associations of technology users and non-users.
Data included may not have been representative of all US diabetes centers, limiting generalizability, while any DKA events that took place outside of medical centers were not included in the analysis.
“Our work shows racial inequities in diabetes care were present before the pandemic, starkly visible during the pandemic, and will continue to persist after the pandemic—unless we systemically root out and target racial inequities in diabetes care,” said lead author Andrew R. Lavik, MD, PhD.
“Minorities continue to be affected by life-threatening yet preventable complications of diabetes more than other groups,” said co-author Nana-Hawa Yayah Jones, MD. “We must redouble our efforts to relieve this burden, both during the COVID-19 pandemic and beyond.”
Lavik AR, Ebekozien O, Noor N, et al. Trends in type 1 diabetic ketoacidosis during COVID-19 surges at seven US centers: highest burden on non-Hispanic Blacks. J Clin Endocrinol Metab. Published online April 5, 2022. doi:10.1210/clinem/dgac158